1,4-二氢-4-氧代喹唑啉-6-羧酸 | 33986-75-3

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 1,4-二氢-4-氧代喹唑啉-6-羧酸
• 中文别名: 3,4-二氢-4-氧杂喹唑啉酮-6-甲酸
• 英文名称: 4-oxo-3,4-dihydroquinazoline-6-carboxylic acid
• 英文别名: 6-carboxy-4(3H)quinazolinone；4-Oxo-3,4-dihydro-chinazolin-6-carbonsaeure；4-Oxo-3,4-dihydroquinazolin-6-carboxylic acid；3,4-Dihydro-4-oxoquinazoline-6-carboxylic acid；4-oxo-3H-quinazoline-6-carboxylic acid
• CAS: 33986-75-3
• 化学式: C₉H₆N₂O₃
• mdl: MFCD09878505
• 分子量: 190.158
• InChiKey: WARFZQDQEUGANF-UHFFFAOYSA-N

物化性质

• 沸点：
  477.2±47.0 °C(Predicted)
• 密度：
  1.56±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 储存条件：
  存储条件：2-8°C，密封保存，干燥环境。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3,4-Dihydro-4-oxoquinazoline-6-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3,4-Dihydro-4-oxoquinazoline-6-carboxylic acid
CAS number: 33986-75-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H6N2O3
Molecular weight: 190.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,4-二氢-4-氧代喹唑啉-6-羧酸 在 氯化亚砜 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 以55%的产率得到4-氧代-3,4-二氢喹唑啉-6-羧酸甲酯
  参考文献：
  名称：

  BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

  摘要：

  揭示了在改善以不需要的钙通道活性为特征的情况下有效的方法和化合物，特别是不需要的T型钙通道活性。具体来说，揭示了一系列含有噻吡嘧啶或氧喹唑啉衍生物的化合物，其具有一般式（1）或式（2），其中X是连接剂，Y是芳香基或N（R5）（R6）。

  公开号：

  US20080280900A1
• 作为产物：
  描述：

  4-氨基-间苯二甲酸 在 formamide 作用下， 以 丙酮 为溶剂， 以50%的产率得到1,4-二氢-4-氧代喹唑啉-6-羧酸
  参考文献：
  名称：

  BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

  摘要：

  揭示了在改善以不需要的钙通道活性为特征的情况下有效的方法和化合物，特别是不需要的T型钙通道活性。具体来说，揭示了一系列含有噻吡嘧啶或氧喹唑啉衍生物的化合物，其具有一般式（1）或式（2），其中X是连接剂，Y是芳香基或N（R5）（R6）。

  公开号：

  US20080280900A1

文献信息

• [EN] FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1<br/>[FR] DÉRIVÉS DE 1,4-DIHYDRODIOXINE FUSIONNÉS À UTILISER EN TANT QU'INHIBITEURS DE FACTEUR DE TRANSCRIPTION 1 DU CHOC THERMIQUE
  申请人：CANCER REC TECH LTD

  公开号：WO2015049535A1

  公开（公告）日：2015-04-09

  The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

  本发明涉及式I的化合物，其中A1、A2、R4和Q如本文所定义。本发明的化合物是热休克因子1（HSF1）的抑制剂。具体来说，本发明涉及将这些化合物用作治疗和/或预防增殖性疾病，如癌症的治疗剂。本发明还涉及制备这些化合物的方法，以及包含它们的药物组合物。
• [EN] NEW AMINO-PYRIMIDONYL-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX DÉRIVÉS D'AMINO-PYRIMIDONYL-PIPÉRIDINYL, LEUR PROCÉDÉ DE PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：SERVIER LAB

  公开号：WO2020079205A1

  公开（公告）日：2020-04-23

  Compounds of formula (I) wherein R1, R2, R3, R4, R5, n and Q are as defined in the description. Medicaments.

  式(I)中R1、R2、R3、R4、R5、n和Q的化合物如描述中所定义。药物。
• [EN] AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES<br/>[FR] DERIVES DE BENZENE A FUSION AZOLIDINONE-VINYLE
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2004007491A1

  公开（公告）日：2004-01-22

  The present invention is related to azolidinedione-vinyl fused-benzene derivatives of formula (I) for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries. Formula (I), wherein A, X, Y, Z, R1 , R2 and n are as described in the description.

  本发明涉及式(I)的噁唑烷二酮-乙烯融合苯衍生物，用于治疗和/或预防自身免疫性疾病和/或炎症性疾病、心血管疾病、神经退行性疾病、细菌或病毒感染、肾脏疾病、血小板聚集、癌症、移植排斥或肺部损伤。式(I)中，A、X、Y、Z、R1、R2和n如描述中所述。
• [EN] HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE WDR5 UTILISÉS EN TANT QUE COMPOSÉS ANTICANCÉREUX
  申请人：NOVARTIS AG

  公开号：WO2021028806A1

  公开（公告）日：2021-02-18

  The present invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; (I) which are inhibitors of WDR5. The present invention also provides pharmaceutical compositions comprising such compounds, compositions comprising such compounds with an additional therapeutic agent and the therapeutic uses of such compounds.

  本发明提供了式（I）的化合物或其药学上可接受的盐；（I）这些化合物是WDR5的抑制剂。本发明还提供了包含这些化合物的药物组合物，包含这些化合物与额外治疗剂的组合物以及这些化合物的治疗用途。
• [EN] QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS<br/>[FR] DÉRIVÉS DE QUINAZOLINONE ET UTILISATION DE CES DÉRIVÉS EN TANT QU'INHIBITEURS DU B-RAF
  申请人：ASTRAZENECA AB

  公开号：WO2006024836A1

  公开（公告）日：2006-03-09

  The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

  该发明涉及化学式（I）的化合物或其药学上可接受的盐，这些化合物具有B Raf抑制活性，因此在抗癌活性方面有用，并且在人类或动物体的治疗方法中有用。 该发明还涉及制造所述化学化合物的方法，含有它们的药物组合物以及它们在制造用于在诸如人类等恒温动物体中产生抗癌效果的药物中的使用。